A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation ...

New research from the IU School of Medicine found a discovery that could lead to new treatments for prostate cancer. The ...

Adcentrx begins patient dosing in phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 to treat advanced solid tumours: San Diego, California Wednesday, ...

Francis Medical Inc., a Twin Cities med-tech manufacturer that's developing a way to treat prostrate and other cancers with water vapor, said Tuesday it raised $80 million in its latest equity funding ...

Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success ...

Discover recent research that sheds light on a promising therapeutic strategy for tackling prostate cancer by targeting the ...

HRS-1167 is under clinical development by Merck and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC).

Researchers found that prostate cancer patients with greater socioeconomic disadvantages were less likely to receive targeted therapy, and participation in the 340B program did not counteract that.

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...